Anzeige
Mehr »
Login
Freitag, 17.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DK4Z | ISIN: FR0014009YQ1 | Ticker-Symbol: F1B
Tradegate
17.01.25
11:18 Uhr
3,130 Euro
+0,015
+0,48 %
Branche
Versorger
Aktienmarkt
Sonstige
1-Jahres-Chart
LHYFE SA Chart 1 Jahr
5-Tage-Chart
LHYFE SA 5-Tage-Chart
RealtimeGeldBriefZeit
3,0903,16520:19
3,1003,15520:22
Actusnews Wire
188 Leser
Artikel bewerten:
(1)

LHYFE: Lhyfe and Masdar join forces to explore the co-development of major green hydrogen production projects

Finanznachrichten News

Lhyfe and Masdar join forces to explore the co-development of major green hydrogen production projects


Nantes (France), 17 January 2025 - 1:30 pm - Lhyfe (EURONEXT: LHYFE), a pioneering producer and supplier of green and renewable hydrogen for mobility and industry, and Abu Dhabi Future Energy Company PJSC - Masdar, the UAE's clean energy leader, have signed a Memorandum of Understanding (MoU) to explore potential co-development opportunities in large-scale green hydrogen production projects in Europe.




The MoU was signed at Abu Dhabi Sustainability Week (ADSW) 2025 and is part of the strategy announced in 2024 by Lhyfe to co-develop projects with financial, industrial investors and experienced partners seeking to invest in green hydrogen production projects.

Through this strategic partnership, the two companies aim to explore collaboration and investment opportunities across the green hydrogen value chain, with a focus on co-developing large projects. This collaboration between two of the leading pioneers in the green hydrogen space will leverage their complementary abilities and support their ambitions to drive and develop the sector.

Lhyfe is one of the pioneers in the green hydrogen sector and is one of the fastest-growing players. Established in 2019, Lhyfe already has four installed green hydrogen production sites in Europe, and several other sites under construction. Lhyfe has demonstrated its industrial capacity to build and operate production sites of increased capacity. Lhyfe's pipeline of projects represents a total installed capacity of 9.5GW and includes several large-scale projects at advanced stages and ready to accelerate. Its proven record as one of the largest developers and operators of commercially active green hydrogen projects in Europe was key for Masdar's decision to enter into the MoU.

Masdar is aiming for a renewable energy portfolio capacity of 100GW by 2030, supporting the target set in the UAE Consensus to triple global renewables capacity by the end of this decade, and aims to be a leading producer of green hydrogen in the same timeframe. It is targeting 1 million tonnes per annum of green hydrogen or equivalent derivatives in the UAE and globally within a decade.
Mohammad Abdelqader El Ramahi, Chief Green Hydrogen Officer, Masdar, said: "Masdar is committed to advancing the development of green hydrogen around the world and we believe Europe will be a significant player in the future green hydrogen sector. This collaboration with Lhyfe will enable us to leverage our shared expertise and resources to explore pathways to accelerating development and potentially supporting our ambitious growth plans."
Matthieu Guesné, Founder and CEO of Lhyfe, said
: "Masdar is one of the most important developers of renewable energies, with real expertise on green hydrogen and a strong lead in terms of deployment. This is evidenced by the large number of industry awards received since 2007 for its renewable energy projects and commitment to innovation. We have a common ambition: to decarbonize industry on a massive scale and as quickly as possible thanks to green hydrogen. By combining our complementary expertise, we want to accelerate the deployment of large sites, which have the capacity to make a difference on greenhouse gas emissions."

About Lhyfe
Lhyfe is a European group devoted to energy transition, and a producer and supplier of green and renewable hydrogen. Its production sites and portfolio of projects seek to provide access to green and renewable hydrogen in industrial quantities, and enable the creation of a virtuous energy model capable of decarbonising entire sectors of industry and transport.
In 2021, Lhyfe inaugurated the first industrial-scale green hydrogen production plant in the world to be interconnected with a wind farm. In 2022, it inaugurated the first offshore green hydrogen production pilot platform in the world.
In 2023, it inaugurated two new sites and currently has several sites under construction or expansion across Europe.
Lhyfe is represented in 12 European countries and had 200 staff at the end of June 2024. The company is listed on the Euronext market in Paris (ISIN: FR0014009YQ1 - LHYFE). Lhyfe.com
Click to access the Lhyfe Media Kit (press releases and visuals)

Contacts:
Industry Press Relations
Nouvelle Graines
Clémence Rebours
+33 (0)6 60 57 76 43
c.rebours@nouvelles-graines.com
Financial Press Relations
ACTUS
Manon Clairet
+33 (0)1 53 67 36 73
mclairet@actus.fr
Investor Relations
LHYFE
Yoann Nguyen
investors@lhyfe.com
------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: yphwkphok2yby3BwZ5WZamWUbmlplGCUmpObyJKeaZicnXJhyZiVbZ2bZnFqmm5o
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-89592-17.01.25_lhyfe-x-masdar-mou_en_final.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2025 Actusnews Wire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.